We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01286571
First Posted: January 31, 2011
Last Update Posted: November 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Boehringer Ingelheim
  Purpose
The objective of this study is to investigate the effect of food on the relative bioavailability of a 50 mg BI 135585 XX tablet.

Condition Intervention Phase
Healthy Drug: BI 135585 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioavailability and Pharmacokinetics of 50 mg BI 135585 XX Administered as Tablet With and Without Food to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Area under the concentration-time curve of BI 135585 in plasma over the time interval from 0 hours extrapolated to infinity [ Time Frame: up to 144 hours post treatment ]
  • Maximum measured concentration of the analyte in plasma of BI 135585 in plasma over the time interval from 0 hours extrapolated to infinity [ Time Frame: up to 144 hours post treatment ]

Secondary Outcome Measures:
  • AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: up to 144 hours post treatment ]
  • Physical examination (occurrence of findings) [ Time Frame: up to 14 days post treatment ]
  • %AUCtz-∞ (percentage of AUC0-∞ obtained by extrapolation) [ Time Frame: up to 144 hours post treatment ]
  • tmax (time from dosing to maximum measured concentration) [ Time Frame: up to 144 hours post treatment ]
  • λz (terminal rate constant in plasma) [ Time Frame: up to 144 hours post treatment ]
  • t1/2 (terminal half-life of the analyte in plasma) [ Time Frame: up to 144 hours post treatment ]
  • MRTpo (mean residence time of the analyte in the body after oral administration) [ Time Frame: up to 144 hours post treatment ]
  • CL/F (total/apparent clearance of the analyte in plasma after extravascular administration) [ Time Frame: up to 144 hours post treatment ]
  • Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: up to 144 hours post treatment ]
  • Vital signs (blood pressure, pulse rate) [ Time Frame: up to 14 days post treatment ]
  • 12-lead ECG (electrocardiogram) [ Time Frame: up to 14 days post treatment ]
  • Clinical laboratory parameters (haematology, enzymes, substrates, electrolytes, hormones of the HPA axis and the thyroid gland, and urinalysis) [ Time Frame: up to 14 days post treatment ]
  • Incidence and severity of Adverse events [ Time Frame: up to 14 days post treatment ]
  • Assessment of tolerability by the investigator [ Time Frame: up to 14 days post treatment ]

Enrollment: 14
Study Start Date: January 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 135585 (T)
single dose per subject as tablet formulation after high fat, high caloric meal
Drug: BI 135585
one oral single dose per subject
Experimental: BI 135585 (R)
single dose per subject as tablet formulation after an overnight fast
Drug: BI 135585
one oral single dose per subject

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

- healthy male subjects

Exclusion criteria:

- Any relevant deviation from healthy conditions

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01286571


Locations
Germany
1283.3.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01286571     History of Changes
Other Study ID Numbers: 1283.3
2010-022697-14 ( EudraCT Number: EudraCT )
First Submitted: January 28, 2011
First Posted: January 31, 2011
Last Update Posted: November 1, 2013
Last Verified: October 2013